BMS’ Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

 BMS’ Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

BMS’ Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

Shots:

  • The approval is based on P-lll SUNBEAM & RADIANCE part B study which involves the assessing of Zeposia (0.92mg and 0.46 mg) vs Avonex (qw, IM) in 1,346 & 1313 patients with RMS for 12 & 24mos. across 158 & 150 sites in 20 & 21 countries respectively
  • Result: relative reduction in ARR (48% & 38%); absolute ARR (0.18 vs 0.35 & 0.17 vs 0.28). reduction in number of T1– weighted GdE (0.16 vs 0.43 & 0.18 vs 0.37); reduction in enlarging T2 brain lesions (1.47 vs 2.84 & 1.84 vs 3.18) respectively
  • Zeposia is the only first line S1P receptor modulator approved in Canada for the treatment of RRMS, acts by decreasing the frequency of clinical exacerbations

    Click here ­to­ read full press release/ article | Ref: News Wire Canada | Image: ME Support

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post